In 2019, the market for Netherton syndrome was valued at approximately US$ 19.57 million and is anticipated to grow to US$ 74.31 million by 2027, reflecting a compound annual growth rate (CAGR) of 20.3% from 2020 to 2027.
The expansion of the Netherton syndrome market can be primarily attributed to several key factors, including an increase in awareness initiatives, a growing number of drug introductions, and a strong pipeline of products in development. Nevertheless, the presence of side effects associated with Netherton syndrome medications poses a challenge to market growth.
Numerous companies globally are dedicated to the creation and advancement of new, effective, and innovative treatments for rare diseases, including Netherton syndrome. This condition is a chronic genetic skin disorder that can become life-threatening, with individuals affected by Netherton syndrome experiencing various immunity-related complications such as food allergies, hay fever, asthma, and eczema, which is characterized by inflammation of the skin.
In May 2020, Azitra, Inc., a company specializing in clinical-stage medical dermatology drugs, was granted Rare Pediatric Disease Designation for ATR-12 by the US Food and Drug Administration (FDA) for its application in treating Netherton syndrome (NS). Additionally, in April 2010, LifeMax Laboratories, Inc. received fast track designation from the FDA for its investigational therapy LM-030, which is currently undergoing a Phase 2/3 pivotal clinical trial for Netherton syndrome and was licensed from Novartis. Furthermore, in July 2020, SixeraPharma introduced a treatment specifically targeting certain proteases in the skin for Netherton syndrome.
Moreover, a significant number of investors are channeling funds into projects aimed at addressing rare diseases. For example, in May 2020, Toronto Innovation Acceleration Partners (TIAP), Evotec SE, and AmorChem II Fund L.P. collectively invested US$ 1.75 million into a drug development initiative focused on Netherton syndrome, a rare skin condition that affects approximately one in 200,000 newborns globally. Consequently, the growing focus on developing treatment options for rare diseases, along with a promising pipeline of drug candidates for Netherton syndrome, is fostering market growth.
The global Netherton syndrome market is categorized by therapy type into several segments: keratolytic agents, oral and topical steroids and retinoids, topical calcineurin inhibitors, biological therapies, and radiation therapies. In 2019, the keratolytic agents segment dominated the market share for Netherton syndrome. The growth of this segment is driven by the increasing number of drug launches and a robust pipeline of products. Additionally, strategic initiatives by service providers, including collaborations, mergers, acquisitions, and expansions aimed at accelerating drug development timelines, are further propelling market growth. Government programs aimed at raising awareness about Netherton syndrome are also expected to positively influence market growth during the forecast period. However, the biological therapy segment within the global Netherton syndrome market is projected to experience significant growth throughout the forecast period.
Key organizations such as the World Health Organization (WHO), the Food and Drug Administration (FDA), the National Health Service (NHS), and the Centers for Disease Control and Prevention (CDC) are among the primary and secondary sources referenced in the preparation of this report.
Â